<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664378</url>
  </required_header>
  <id_info>
    <org_study_id>CCL07001</org_study_id>
    <nct_id>NCT00664378</nct_id>
  </id_info>
  <brief_title>Efficacy Study of CYT997 in Multiple Myeloma</brief_title>
  <official_title>A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study that is designed to test the safety of CYT997 when given to&#xD;
      patients with multiple myeloma and to test if CYT997 has any activity against that cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty enrolling patients&#xD;
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma</measure>
    <time_frame>Baseline to study completion</time_frame>
    <description>The overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma once every 3 week cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cycles required to achieve maximum response</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Relapsed and Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYT997</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT997</intervention_name>
    <description>Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma per International Working Group (IWG) criteria&#xD;
&#xD;
          -  Have received at least 1 but no more than 4 prior lines of therapy&#xD;
&#xD;
          -  Have failed to respond to the most recently administered anti-myeloma therapy&#xD;
&#xD;
          -  Have a life expectancy of at least 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 3&#xD;
&#xD;
          -  At registration absolute neutrophil count &gt; 1x10^9/L and platelet count &gt; 50 x 10^9/L&#xD;
             unsupported&#xD;
&#xD;
          -  At registration bilirubin less than 1.5 x upper limit of normal and transaminases less&#xD;
             than 2 x upper limit of normal and serum creatinine less than 0.19 mmol/L&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Must agree to adequate contraceptive measure if indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with monoclonal gammopathy of undetermined significance&#xD;
&#xD;
          -  Known or suspected hypersensitivity to CYT997&#xD;
&#xD;
          -  Patient with uncontrolled intercurrent illness&#xD;
&#xD;
          -  Active infections or other illnesses that precludes chemotherapy administration or&#xD;
             patient compliance.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients who have received any other investigational agents in the last 3 weeks prior&#xD;
             to the start of treatment.&#xD;
&#xD;
          -  Patients with the following conditions will be excluded:&#xD;
&#xD;
               -  myocardial infarction or stroke within 6 months&#xD;
&#xD;
               -  unstable angina pectoris or acute ischemic changes on ECG&#xD;
&#xD;
               -  history of diabetic retinopathy&#xD;
&#xD;
               -  symptomatic peripheral arterial disease&#xD;
&#xD;
               -  major surgery in the last 30 days&#xD;
&#xD;
          -  Patients with uncontrolled diarrhea despite optimal medication and those with any&#xD;
             history of acute gastrointestinal bleeding&#xD;
&#xD;
          -  Patients with a baseline prolongation of the QTc interval of Common Terminology&#xD;
             Criteria (CTC) Grade 1 (QTc &gt; 0.45-0.47 sec) or greater&#xD;
&#xD;
          -  Patients with impaired cardiac function or clinically significant cardiac diseases,&#xD;
             including any one of the following:&#xD;
&#xD;
               -  left ventricular ejection fraction (LVEF) &lt; 45% as determined by multigated&#xD;
                  acquisition (MUGA) scan or echocardiogram;&#xD;
&#xD;
               -  complete left bundle branch block;&#xD;
&#xD;
               -  obligate use of a cardiac pacemaker;&#xD;
&#xD;
               -  congenital long QT syndrome;&#xD;
&#xD;
               -  history or presence of ventricular tachyarrhythmia;&#xD;
&#xD;
               -  presence of unstable atrial fibrillation (ventricular response &gt; 100 bpm).&#xD;
                  -Patients with stable atrial fibrillation are eligible, provided they do not meet&#xD;
                  any of the other cardiac exclusion criteria;&#xD;
&#xD;
               -  clinically significant resting bradycardia (&lt; 50 bpm);&#xD;
&#xD;
               -  right bundle branch block + left anterior hemiblock (bifascicular block);&#xD;
&#xD;
               -  angina pectoris ≤ 3 months prior to starting study drug;&#xD;
&#xD;
               -  acute myocardial infarction (MI) ≤ 3 months prior to starting study drug; or&#xD;
&#xD;
               -  other clinically significant heart disease (e.g., congestive heart failure (CHF),&#xD;
                  uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
                  compliance with an antihypertensive regimen).&#xD;
&#xD;
          -  Patients currently receiving treatment with medications known to prolong the QTc&#xD;
             interval and/or to induce Torsades de Pointes arrhythmia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Spencer, Assoc Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Myeloma Research Group, The Alfred Hospital, Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <disposition_first_submitted>April 25, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 3, 2013</disposition_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma, relapsed, refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

